

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| PPLICATION NO. | F | ILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO |
|---------------------|----------------------|------------|----------------------|---------------------|-----------------|
| 10/616,046 | 0/616,046 07/08/2003 | | Mladen Mercep | 03818/100L652-US1 | 9782 |
| 7278 | 7590 | 01/25/2005 | | EXAMINER | |
| DARBY & P. O. BOX 5 | | P.C. | PESELEV, ELL! | | |
| NEW YORK | | 0150-5257 | | ART UNIT | PAPER NUMBER |
| | • | | | 1623 | |

DATE MAILED: 01/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | Application No. | Applicant(s) | | | | |
|---|--|---|---|--|--|--|--|
| | | 10/616,046 | MERCEP ET AL. | | | | |
| | Office Action Summary | Examiner | Art Unit | | | | |
| | | Elli Peselev | 1623 | | | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply | | | | | | | |
| THE MA - Extension after SIX - If the peri - If NO per - Failure to Any reply | RTENED STATUTORY PERIOD FOR REPLY ILING DATE OF THIS COMMUNICATION. In this of time may be available under the provisions of 37 CFR 1.1 (6) MONTHS from the mailing date of this communication. It is is is is that thirty (30) days, a reply is of for reply is specified above, the maximum statutory period is reply within the set or extended period for reply will, by statute or received by the Office later than three months after the mailing atent term adjustment. See 37 CFR 1.704(b). | 36(a). In no event, however, may a reply be time y within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE | ely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133). | | | | |
| Status | • | | | | | | |
| 1)⊠ R€ | esponsive to communication(s) filed on <u>08 D</u> | <u>ecember 2004</u> . | | | | | |
| | | action is non-final. | | | | | |
| | Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. | | | | | | |
| Disposition | of Claims | | | | | | |
| 4a) 5)□ Cla 6)⊠ Cla 7)□ Cla | aim(s) <u>1,2 and 9-52</u> is/are pending in the app Of the above claim(s) is/are withdrawaim(s) is/are allowed. aim(s) <u>1,2 and 9-52</u> is/are rejected. aim(s) is/are objected to. aim(s) are subject to restriction and/o | wn from consideration. | | | | | |
| Application | Papers | | | | | | |
| 9)[The | e specification is objected to by the Examine | er. | | | | | |
| 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. | | | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | | | | | | |
| Priority und | er 35 U.S.C. § 119 | | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | | | |
| Attachment(s) | | | | | | | |
| 2) Notice of3) Information | References Cited (PTO-892) Draftsperson's Patent Drawing Review (PTO-948) on Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | | • | | | | |
| Paper No(s)/Mail Date 6) Uther: | | | | | | | |

۲.

Application/Control Number: 10/616,046

Art Unit: 1623

Claims 1 and 36-51 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a linking group represented by the Formula IV, does not reasonably provide enablement for any linking group for the reasons set forth in the Office Action of August 10, 2004.

Applicant's arguments filed December 8, 2004 have been considered but have not been found persuasive.

The specification fails to provide a specific defination for the linking group. Note that on page 17 of the specification it is stated that "L can be selected to be a linking group represented by the Formula IV". However, said defination is not limited to the group of formula IV. The specification fails to provide any guidance or teaching on how to chose linking groups which do not have Formula IV. Since the terminology "linking group" encompasses a large number of possible groups, it would take an undue amount of experimentation to determine which specific linking groups will result in a compound having the desired activity.

Claim 45 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement for the reasons set forth in the Office Action of August 10, 2004 i.e. there is no evidence of record that the anti-viral compounds encompassed by said claim possess anti-HIV activity.

Claims 1-2 and 9-52 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 10/616,046

Art Unit: 1623

The terminology "and pharmaceutically acceptable salts and solvates thereof and individual diastereoisomers thereof" (claim 1) and "and pharmaceutically acceptable salts and solvates therefrom" (claims 2 and 14-35) is an improper Markush terminology. Such terminology as "or a pharmaceutically acceptable salt or solvate thereof or an individual diastereoisomer thereof" and "or pharmaceutically acceptable salt or solvate thereof" can be used to overcome the rejection.

Claim 2 is indefinite in that it contains two definations of the variable L. Adding the term "or" between the two definations can be used to overcome the rejection. Also the term "and" or "or" should be added beween the definations (iii) and (iv) of the variable V in claims 2 and 36.

Regarding claim 38, the phrase "especially" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

A period is missing at the end of claim 52.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Application/Control Number: 10/616,046

Art Unit: 1623

4 ... 4

shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later

than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Elli Peselev whose telephone number is (571) 272-

0659. The examiner can normally be reached on 9.00-5.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, James Wilson can be reached on (571) 272-0661. The fax phone number

for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Elli Peselev

PRIMARY EXAMINER GROUP 1200

Page 4